REGULATORY
Label Revisions Ordered for Antihypertensives, Adalimumab, I/O Meds, and More
The Ministry of Health, Labor and Welfare (MHLW) on September 9 ordered safety-related label changes for 27 antihypertensive drugs, including azilsartan, as well as several other medicines across different therapeutic areas. For the antihypertensives, the description of clinically significant adverse…
To read the full story
Related Article
- PMDA Flags New Potential Risks for RAS Agents and Others
August 12, 2025
REGULATORY
- Avastin Price to Be Axed by 45% as G1 Rule Hits Originator Biologics
March 6, 2026
- Forxiga Slapped with 36% Price Cut on PMP Return in FY2026 Revision
March 6, 2026
- Japan Panel Clears Joenja, Dojolvi, Bayer MRI Contrast Agent
March 6, 2026
- Japan's Revised Drug Distribution Guidelines Take Effect
March 6, 2026
- Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





